About this trial
This is an international, multi-center, randomised, open-label, superiority phase III trial of elacestrant vs standard endocrine therapy. During the screening ctDNA phase, patients will be tested at different timepoints to detect the presence of ctDNA in their blood. Patients who are found to be ctDNA-positive and have no evidence of distant metastasis or locoregional recurrence, will be randomised 1:1 between standard endocrine treatments (the same they were receiving when tested ctDNA positive) versus elacestrant, provided they meet all eligibility criteria.
Patient Profile
For patients with ER+/HER2- early-stage breast cancer with ctDNA relapse.
Where’s this trial being run?
St James’s Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | TREAT ctDNA study |
|---|---|
| Number: | 23-03 |
| Full Title: | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse |
| Principal Investigator: | Prof. Cathy Kelly |
|---|---|
| Type: | Collaborative |
| Sponsor: | EORTC |
| Recruitment Started: |
Global: 15-Dec-2023 Ireland: 12-Sep-2024 |
| Global Recruitment Target: | 220 |
|---|---|
| Ireland Recruitment Target: | 12 |